Compare e l f Beauty Inc (ELF) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Neurocrine Biosciences Inc — how do they compare? e l f Beauty Inc trades at $94.65 (market cap $5.62B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 3× e l f Beauty Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ELF | NBIX | |
|---|---|---|
Market Cap | $5.62B | $16.76B |
Sector | Technology | Health |
52-Week High | $146.67 | $185.50 |
52-Week Low | $49.57 | $123.10 |
Enterprise Value | $6.20B | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF trades at $98.49, up 6.69% in 24 hours, near its 52-week high. The stock exhibits a bullish technical trend with strong support at $93 and resistance at $101. Recent Q2 2026 earnings beat expectations with EPS of $1.75 versus $0.71 expected, driven by 36% revenue growth and the Rhode acquisition. The company raised fiscal 2027 guidance, reflecting robust demand and international expansion.
Outlook remains positive due to consistent sales growth and strategic initiatives, but risks include high valuation (P/E 97.18) and reliance on acquisitions for growth. The stock offers growth potential but faces margin pressure from increased investments and competitive dynamics in the beauty sector.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
